TMB Substrate Set

Pricing & Availability
Regulatory Status
Other Names
TMB Substrate
Ave. Rating
Submit a Review
Product Citations
Cat # Size Price Quantity Check Availability Save
421101 110 ml x 2 $42
Check Availability

Need larger quantities of this item?
Request Bulk Quote

The TMB Substrate Set contains 110 ml TMB Substrate A and 110 ml TMB Substrate B, sufficient for twenty 96-well plates. It is formulated with 3, 3', 5, 5' tetramethyl benzidine (TMB). The substrate can be catalyzed with peroxidase to produce a pale blue color which can be read spectrophotometrically at 370 or 620-650 nm. The TMB reaction may be stopped with BioLegend's Stop Solution (Cat. No. 423001), and read at 450 nm.

Product Details
Technical data sheet

Product Details

Storage & Handling
The TMB Substrate Set (TMB Substrate A and TMB Substrate B) should be stored between 2°C and 8°C. Avoid prolonged exposure to light, contact with metal, air, or extreme temperatures.


Recommended Usage

TMB Substrate A should be clear and colorless.
TMB Substrate B should be colorless to a very light amber.
TMB Substrate is the mixture of equal volumes of TMB Substrate A with TMB Substrate B. For example, for one plate, mix 5.5 ml TMB Substrate A with 5.5 ml of TMB Substrate B in a clean container. Mix immediately before use.
After mixing the reagents together, TMB substrate working solution should be colorless or very faint blue.

Application Notes

Warm to room temperature prior to use. To prepare a working solution, mix equal volumes of TMB Substrate A and TMB Substrate B. Prepare only the amount needed for each assay run. After wells are completely washed, to remove unbound antibody and HRP, add 100 µl to 200 µl substrate solution to each well. Discard any remaining working solution after use. For endpoint assays, add 50 µl to 100 µl of Stop Solution (2N H2SO4 or 1M H3PO4), which changes the color from blue to yellow. Read at 450 nm (minus 570 nm for wavelength correction) within 30 minutes of stopping the reaction. For kinetic assays, read the blue color at 620 - 650 nm.

Application References

(PubMed link indicates BioLegend citation)
  1. Kim MS, et al. 2008. J Biochem. 143:497. PubMed
  2. McNally A, et al. 2011. PNAS. 108:7529. PubMed
  3. Santiago FW, et al. 2012. Vaccine. 30:4606. PubMed
  4. Wan LY, et al. 2014. Toxicol Sci. PubMed
  5. de Pablo P, et al. 2014. Ann Rheum Dis. 73:580. PubMed
Product Citations
  1. Jameie F, et al. 2021. Iran J Parasitol. 1:16. PubMed
  2. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  3. Wenzek C, et al. 2022. iScience. 25:105540. PubMed
  4. Bryant JD, et al. 2021. Brain Behav Immun. 97:204. PubMed
  5. Jameie F, et al. 2020. Arch Razi Inst. 75:327. PubMed
  6. Liu W, et al. 2016. J Virol. 90: 8496 - 8508. PubMed
  7. Hsiue EH, et al. 2021. Science. 371:. PubMed
  8. Peng L, et al. 2022. Cell Rep. 40:111160. PubMed
  9. Fertey J, et al. 2021. Methods Mol Biol. 2414:97. PubMed
  10. He Y, et al. 2021. Bio Protoc. 11:e3905. PubMed
  11. Brooks JF, et al. 2020. J Immunol. 205:1239. PubMed
  12. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  13. Stebegg M, et al. 2019. Nat Commun. 2.113194444. PubMed
  14. Lee JL, et al. 2022. Aging Cell. 21:e13692. PubMed
  15. Alapati T, et al. 2021. Genes (Basel). 13:. PubMed
  16. Chang JH, et al. 2022. Vaccines (Basel). 10:. PubMed
  17. Sari AN, et al. 2022. Cancers (Basel). 14:. PubMed
  18. Walczewska M, et al. 2017. Adv Exp Med Biol. 10.1007/978-94-024-1079-2_41. PubMed
  19. Sen K, et al. 2021. Front Immunol. 12:733539. PubMed
  20. Han JP, et al. 2022. Sci Adv. 8:eabj6901. PubMed
  21. Ding P, et al. 2022. Cell Rep. 39:110851. PubMed
  22. Malik V, et al. 2020. Int J Mol Sci. 21:00. PubMed
  23. Ramos-Pinto L, et al. 2021. Animals (Basel). 11:. PubMed
  24. Wu J, et al. 2020. Immunity. 53:115. PubMed
  25. Nuvolone M, et al. 2017. PLoS One. 12:e0171923. PubMed
  26. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  27. Oh E, et al. 2018. Front Oncol. 0.716666667. PubMed
  28. Schwaderer J, et al. 2020. Cell Death Dis. 11:154. PubMed
  29. Debernardi S, et al. 2020. PLoS Med. 17:e1003489. PubMed
  30. Morgan S, et al. 2016. J Immunol. 196: 5014 - 5023. PubMed
  31. Younis RH, et al. 2021. Front Immunol. 596646:12. PubMed
  32. Fang Z, et al. 2022. Nat Commun. 13:3250. PubMed
  33. Groeneveld D, et al. 2020. J Hepatol. 72:146. PubMed
  34. Nogales A, et al. 2017. Virology. 500:1-10. PubMed
  35. Wan L, et al. 2014. Toxicol Sci. 139:83. PubMed
  36. Pagan JD, et al. 2018. Cell. 172:564. PubMed
  37. Del Alcazar D, et al. 2019. Cell Rep. 28:3047. PubMed
  38. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  39. Sun L, et al. 2021. Sci Rep. 11:12477. PubMed
  40. Wu J, et al. 2021. Nat Cell Biol. 23:75. PubMed
  41. Uematsu T, et al. 2016. Sci Rep. 6:37815. PubMed
  42. Yang K, et al. 2020. Cell Chem Biol. 27:866. PubMed
  43. Garg S, et al. 2019. Biotechniques. 67:166. PubMed
  44. Falck-Jones S, et al. 2021. J Clin Invest. 131: . PubMed
  45. Vijver SV, et al. 2021. Front Immunol. 12:733561. PubMed
  46. Barbier M, et al. 2022. Front Immunol. 13:948431. PubMed
  47. Surawut S, et al. 2017. Sci Rep. 7:40006. PubMed
  48. McNally A, et al. 2011. Proc Natl Acad Sci U S A. 108:7529. PubMed
  49. Kim M, et al. 2008. J Biochem. 143:497. PubMed
  50. Strazza M, et al. 2022. Mol Ther Methods Clin Dev. 27:380. PubMed
  51. Pedicone C, et al. 2022. iScience. 25:104170. PubMed
  52. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  53. Salehi S, et al. 2017. PLoS One. 10.1371/journal.pone.0163614. PubMed
  54. Miller H, et al. 2021. J Clin Microbiol. 59:e0096421. PubMed
  55. Leppkes M, et al. 2020. EBioMedicine. 58:102925. PubMed
  56. Parrish H, et al. 2016. Proc Natl Acad Sci U S A. 113: 3000 - 3005. PubMed
  57. Pablo P, et al. 2014. Ann Rheum Dis. 73:580. PubMed
  58. Guo Y, et al. 2021. Nat Commun. 12:2623. PubMed
  59. Reis B, et al. 2021. Mar Drugs. 19:. PubMed
  60. Knopf J, et al. 2022. Cells. 11:. PubMed
  61. Yang E, et al. 2015. Acta Biochim Biophys Sin. 47: 588-596. PubMed
  62. Santiago F, et al. 2012. Vaccine. 30:4606. PubMed
  63. Lee KS, et al. 2022. iScience. 25:105038. PubMed
  64. Yang K, et al. 2021. STAR Protoc. 2:100288. PubMed

Antigen Details

Gene ID

Related FAQs

What is the difference between your two substrate solutions: TMB Substrate Reagent Set (Cat. No. 421101) and TMB High Sensitivity Substrate Solution (Cat. No. 421501)?

TMB Substrate Reagent Set (Cat. No. 421101) contains two components, which need to be mixed immediately prior to use. The TMB High Sensitivity Substrate Solution (Cat. No. 421501) contains everything in one solution with special stabilizers. It is a high kinetic substrate solution which generally gives higher signal. The type of substrate used for an assay can affect the optical density (OD) achievable and the time required to achieve the desired OD.

Go To Top Version: 4    Revision Date: 05/30/2017

For Research Use Only. Not for diagnostic or therapeutic use.


This product is supplied subject to the terms and conditions, including the limited license, located at ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.


BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.


8999 BioLegend Way, San Diego, CA 92121
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587


Remember me
Forgot your password? Reset Password
Request an Account